Murat Yuksel
Research Subjects
Research Interests
Murat Yuksel has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Duygu Durna Corum
University of Hatay Mustafa Kemal
7 shared publications - Kamil Uney
University of Selcuk
7 shared publications - Orhan Corum
University of Hatay Mustafa Kemal
7 shared publications - Devran Coskun
Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, University of Siirt, Siirt 56100, Türkiye
5 shared publications - Erdinc Turk
University of Hatay Mustafa Kemal
5 shared publications - Mehmet Bugra Kivrak
SİVAS CUMHURİYET ÜNİVERSİTESİ, VETERİNER FAKÜLTESİ, KLİNİK BİLİMLER BÖLÜMÜ, VETERİNERLİK DOĞUM VE JİNEKOLOJİSİ ANABİLİM DALI
3 shared publications
Latest Publications
- Open Access
- 17 November 2026
- Published by Springer Nature in BMC Veterinary Research
Pharmacokinetics of flunixin across different stages of gestation: a controlled study in goats
- 17 November 2026
- Published by Springer Nature in BMC Veterinary Research
Open AccessPharmacokinetics of flunixin across different stages of gestation: a controlled study in goats
- 17 August 2026
- Published by Wiley in Journal of Veterinary Pharmacology and Therapeutics
Comparative Pharmacokinetics of Levamisole in Pregnant and Non‐Pregnant Ewes: A Longitudinal Study
The influence of the state of pregnancy (days 45, 90, and 135 of gestation) on the pharmacokinetics of levamisole was investigated in ewes. Twelve healthy Merino female sheep were allocated into two groups ( n = 6 per group). The ewes in group 1 (non‐pregnant) were not mated, while the ewes in group 2 (pregnant) were mated with rams by synchronizing their estrus cycles. Levamisole was injected intramuscularly once at a dose of 7.5 mg/kg into all ewes. Blood samples were taken at 13 different times over a 48‐h period according to a defined protocol. Plasma samples were analyzed for levamisole via high‐performance liquid chromatography. Pregnant ewes had significantly lower C max , AUC 0‐last , and t 1/2ʎz of levamisole than non‐pregnant ewes. There were no significant differences in T max between the two groups. The values of AUC 0‐last , C max , and t 1/2ʎz decreased as pregnancy progressed. These results indicated that pregnancy reduced exposure (AUC 0‐last ) and duration of levamisole presence in the body. This information contributes to the use of levamisole in pregnant ewes, but further studies are needed to determine the change in therapeutic effect related to pregnancy.
- 17 August 2026
- Published by Wiley in Journal of Veterinary Pharmacology and Therapeutics
Comparative Pharmacokinetics of Levamisole in Pregnant and Non‐Pregnant Ewes: A Longitudinal Study
The influence of the state of pregnancy (days 45, 90, and 135 of gestation) on the pharmacokinetics of levamisole was investigated in ewes. Twelve healthy Merino female sheep were allocated into two groups ( n = 6 per group). The ewes in group 1 (non‐pregnant) were not mated, while the ewes in group 2 (pregnant) were mated with rams by synchronizing their estrus cycles. Levamisole was injected intramuscularly once at a dose of 7.5 mg/kg into all ewes. Blood samples were taken at 13 different times over a 48‐h period according to a defined protocol. Plasma samples were analyzed for levamisole via high‐performance liquid chromatography. Pregnant ewes had significantly lower C max , AUC 0‐last , and t 1/2ʎz of levamisole than non‐pregnant ewes. There were no significant differences in T max between the two groups. The values of AUC 0‐last , C max , and t 1/2ʎz decreased as pregnancy progressed. These results indicated that pregnancy reduced exposure (AUC 0‐last ) and duration of levamisole presence in the body. This information contributes to the use of levamisole in pregnant ewes, but further studies are needed to determine the change in therapeutic effect related to pregnancy.
- Open Access
- 13 August 2026
- Published by Wiley in Reproduction in Domestic Animals
- Vol. 61 (8)
Comparative Investigation of GnRH ‐Immunocastration and a Phytogenic Feed Additive on Reproductive Parameters, Testicular Echogenicity and Behavioural Activity in Young Holstein Bulls
Managing aggressive behaviour in bulls often involves a trade‐off between handling ease and the anabolic benefits associated with endogenous testosterone production. This study compared the effects of GnRH‐immunocastration and a phytogenic feed additive on reproductive parameters, testicular echotexture and behavioural activity in young Holstein bulls aged 12–15 months. Bulls were allocated to either an immunocastration group (IC, n = 6) or a phytogenic feed additive group (PFA, n = 7). The IC group received two subcutaneous injections of 1 mL Bopriva (400 μg GnRH‐protein conjugate) at a three‐week interval, whereas the PFA group received 50 g/day of a phytogenic feed additive throughout the 90‐day experimental period. Evaluations included scrotal circumference (SC), serum testosterone concentrations, ultrasonographic testicular echotexture assessed by mean grey value (MGV) and behavioural observations. Repeated measurements obtained throughout the study were analysed using linear mixed models. Significant group × time interactions ( p < 0.001) were observed for SC, testosterone concentrations and MGV. In the IC group, testosterone concentrations and SC progressively decreased beginning on Day 15, while MGV values declined from Day 30 onward. In contrast, the PFA group maintained relatively stable testosterone concentrations and ultrasonographic echotexture throughout the observation period. Qualitative behavioural observations indicated reduced mounting attempts and restlessness in both groups during the follow‐up period. Immunocastration induced marked suppression of reproductive parameters and alterations in testicular echotexture in young bulls. Under the conditions of this study, supplementation with the phytogenic feed additive was associated with relatively stable reproductive parameters, while qualitative reductions in behavioural activity were also observed. Further studies including untreated control groups and quantitative behavioural scoring systems are warranted.
- 13 August 2026
- Published by Wiley in Reproduction in Domestic Animals
- Vol. 61 (8)
Open AccessComparative Investigation of GnRH ‐Immunocastration and a Phytogenic Feed Additive on Reproductive Parameters, Testicular Echogenicity and Behavioural Activity in Young Holstein Bulls
Managing aggressive behaviour in bulls often involves a trade‐off between handling ease and the anabolic benefits associated with endogenous testosterone production. This study compared the effects of GnRH‐immunocastration and a phytogenic feed additive on reproductive parameters, testicular echotexture and behavioural activity in young Holstein bulls aged 12–15 months. Bulls were allocated to either an immunocastration group (IC, n = 6) or a phytogenic feed additive group (PFA, n = 7). The IC group received two subcutaneous injections of 1 mL Bopriva (400 μg GnRH‐protein conjugate) at a three‐week interval, whereas the PFA group received 50 g/day of a phytogenic feed additive throughout the 90‐day experimental period. Evaluations included scrotal circumference (SC), serum testosterone concentrations, ultrasonographic testicular echotexture assessed by mean grey value (MGV) and behavioural observations. Repeated measurements obtained throughout the study were analysed using linear mixed models. Significant group × time interactions ( p < 0.001) were observed for SC, testosterone concentrations and MGV. In the IC group, testosterone concentrations and SC progressively decreased beginning on Day 15, while MGV values declined from Day 30 onward. In contrast, the PFA group maintained relatively stable testosterone concentrations and ultrasonographic echotexture throughout the observation period. Qualitative behavioural observations indicated reduced mounting attempts and restlessness in both groups during the follow‐up period. Immunocastration induced marked suppression of reproductive parameters and alterations in testicular echotexture in young bulls. Under the conditions of this study, supplementation with the phytogenic feed additive was associated with relatively stable reproductive parameters, while qualitative reductions in behavioural activity were also observed. Further studies including untreated control groups and quantitative behavioural scoring systems are warranted.
- Open Access
- 12 June 2026
- Published by Wiley in Veterinary Medicine and Science
- Vol. 12 (4) , e71024
Pharmacokinetics and Bioavailability of Tolfenamic Acid in Calves: First Evaluation of Subcutaneous Administration
Objective: Tolfenamic acid (TA) is a non‐steroidal anti‐inflammatory drug that is commonly used in veterinary medicine. However, information on its pharmacokinetics in calves, particularly following subcutaneous (SC) administration, is limited. The aim of this study was to characterize the disposition of TA in calves following SC, intramuscular (IM) and intravenous (IV) administration. Methods: Six calves received TA at a dose of 4 mg/kg via each route in a crossover design. Results: TA exhibited route‐dependent pharmacokinetics. The terminal elimination half‐life increased significantly from IV (6.64 h) to IM (12.79 h) and SC (15.11 h) administration, which is consistent with flip‐flop kinetics following extravascular dosing. Following IV administration, the volume of distribution at steady state was moderate (0.67 L/kg), which suggests extensive plasma protein binding. The time to reach the maximum concentration was similar for the IM and SC routes. However, systemic exposure was markedly lower following SC administration, with peak plasma concentration , area under the curve and bioavailability being approximately half of those observed following IM injection. Plasma concentrations exceeded the EC 50 values required to inhibit prostaglandin E 2 and related inflammatory mediators for up to 24 h after IV administration and up to 48 h after IM or SC administration. Conclusions: These findings demonstrate that SC administration of TA in calves results in prolonged but reduced systemic exposure compared with IM administration. The results support the need for route‐specific dosing considerations and provide a basis for further studies on residue depletion and determination of withdrawal period in food‐producing calves.
- 12 June 2026
- Published by Wiley in Veterinary Medicine and Science
- Vol. 12 (4) , e71024
Open AccessPharmacokinetics and Bioavailability of Tolfenamic Acid in Calves: First Evaluation of Subcutaneous Administration
Objective: Tolfenamic acid (TA) is a non‐steroidal anti‐inflammatory drug that is commonly used in veterinary medicine. However, information on its pharmacokinetics in calves, particularly following subcutaneous (SC) administration, is limited. The aim of this study was to characterize the disposition of TA in calves following SC, intramuscular (IM) and intravenous (IV) administration. Methods: Six calves received TA at a dose of 4 mg/kg via each route in a crossover design. Results: TA exhibited route‐dependent pharmacokinetics. The terminal elimination half‐life increased significantly from IV (6.64 h) to IM (12.79 h) and SC (15.11 h) administration, which is consistent with flip‐flop kinetics following extravascular dosing. Following IV administration, the volume of distribution at steady state was moderate (0.67 L/kg), which suggests extensive plasma protein binding. The time to reach the maximum concentration was similar for the IM and SC routes. However, systemic exposure was markedly lower following SC administration, with peak plasma concentration , area under the curve and bioavailability being approximately half of those observed following IM injection. Plasma concentrations exceeded the EC 50 values required to inhibit prostaglandin E 2 and related inflammatory mediators for up to 24 h after IV administration and up to 48 h after IM or SC administration. Conclusions: These findings demonstrate that SC administration of TA in calves results in prolonged but reduced systemic exposure compared with IM administration. The results support the need for route‐specific dosing considerations and provide a basis for further studies on residue depletion and determination of withdrawal period in food‐producing calves.
- 4 May 2026
- Published by Wiley in Journal of Veterinary Pharmacology and Therapeutics
- Vol. 49 (5) , 525-532
Pharmacokinetic Profiles of Enrofloxacin and Its Metabolite Ciprofloxacin Administered by Different Doses in Calves
This research studied dose‐dependent changes in the pharmacokinetics of enrofloxacin (ENR) and its active metabolite, ciprofloxacin (CIP), in calves. The research was performed on eighteen calves utilizing a parallel pharmacokinetic approach. Calves were divided into three distinct dosage groups, receiving intravenous administration of ENR at doses of 2.5, 5, and 10 mg/kg, respectively. Blood samples were collected at 15 specified intervals during a 48‐h duration. ENR and CIP plasma concentrations were quantified by HPLC. Pharmacokinetic data was obtained using non‐compartmental analysis. The area under the concentration‐time curve from 0 to last (AUC 0‐last )/dose of ENR increased in a dose‐dependent manner. The elimination half‐life of ENR was prolonged from 2.41 to 3.47 h ( p < 0.05). The total body clearance decreased significantly with the dose increase ( p < 0.05), while the volume of distribution at steady state remained comparable across dosage groups ( p > 0.05). The AUC 0‐last of CIP increased in a dose‐dependent manner ( p < 0.05), but no alteration was found in the conversion ratio of ENR to CIP (26%–28%, p > 0.05). The results of the current investigation demonstrated that the pharmacokinetics of ENR and CIP in calves had considerable variability with dose. Assessing dose‐dependent pharmacokinetic alterations in calves can aid in establishing the dosing regimen; however, additional research is required to confirm dose‐dependent therapeutic efficacy and safety.
- 4 May 2026
- Published by Wiley in Journal of Veterinary Pharmacology and Therapeutics
- Vol. 49 (5) , 525-532
Pharmacokinetic Profiles of Enrofloxacin and Its Metabolite Ciprofloxacin Administered by Different Doses in Calves
This research studied dose‐dependent changes in the pharmacokinetics of enrofloxacin (ENR) and its active metabolite, ciprofloxacin (CIP), in calves. The research was performed on eighteen calves utilizing a parallel pharmacokinetic approach. Calves were divided into three distinct dosage groups, receiving intravenous administration of ENR at doses of 2.5, 5, and 10 mg/kg, respectively. Blood samples were collected at 15 specified intervals during a 48‐h duration. ENR and CIP plasma concentrations were quantified by HPLC. Pharmacokinetic data was obtained using non‐compartmental analysis. The area under the concentration‐time curve from 0 to last (AUC 0‐last )/dose of ENR increased in a dose‐dependent manner. The elimination half‐life of ENR was prolonged from 2.41 to 3.47 h ( p < 0.05). The total body clearance decreased significantly with the dose increase ( p < 0.05), while the volume of distribution at steady state remained comparable across dosage groups ( p > 0.05). The AUC 0‐last of CIP increased in a dose‐dependent manner ( p < 0.05), but no alteration was found in the conversion ratio of ENR to CIP (26%–28%, p > 0.05). The results of the current investigation demonstrated that the pharmacokinetics of ENR and CIP in calves had considerable variability with dose. Assessing dose‐dependent pharmacokinetic alterations in calves can aid in establishing the dosing regimen; however, additional research is required to confirm dose‐dependent therapeutic efficacy and safety.
- 29 April 2026
- Published by Erciyes Universitesi (DergiPark) in Erciyes Üniversitesi Veteriner Fakültesi Dergisi
- Vol. 23 (1) , 49-58
Diagnostic Performance of Transrectal, Transvaginal, and Transabdominal Ultrasonography in Pregnancy Diagnosis in Ewes
The aim of this study was to evaluate and compare the diagnostic efficiency of transvaginal (tvUSG) and transabdominal (taUSG) ultrasonography on the 21st, 35th, and 50th days of pregnancy in ewes, using transrectal ultrasonography (trUSG) as the reference method. A total of 100 Awassi ewes in anoestrus were used in the study. Ewes were mated after estrus synchronisation. Pregnancy diagnosis was performed using only tvUSG and trUSG on Day 21 post-mating, whereas on Days 35 and 50, taUSG was additionally applied, allowing the use of all three imaging modalities. In tvUSG, the sensitivity on Days 21, 35, and 50 was 85.71%, 95.34%, and 87.80%, respectively, while specificity remained 100.0% at all time points. The positive predictive value was 100.0%, and the negative predictive value was 87.93%, 96.61%, and 91.18%, respectively. Overall accuracy was calculated as 93.00%, 98.00%, and 95.00% on Days 21, 35, and 50 (Kappa=0.860; 0.959; 0.895, P<0.001). Conversely, taUSG demonstrated a sensitivity of 88.37% on Day 35 and 95.12% on Day 50, with accuracy values of 95.00% and 98.00%, respectively (Kappa 0.897; 0958, P<0.001). When the mean examination times were evaluated, tvUSG had the shortest diagnostic time with 110.03±3.09 seconds and 57.06±1.19 seconds on days 21 and 35, respectively, while taUSG was by far the fastest method with 50.12±1.40 seconds on day 50 (P<0.001). In conclusion, tvUSG emerges as an alternative to trUSG for early pregnancy diagnosis, whereas taUSG is clinically more practical in later stages of gestation due to its ease of application and shorter examination time.
- 29 April 2026
- Published by Erciyes Universitesi (DergiPark) in Erciyes Üniversitesi Veteriner Fakültesi Dergisi
- Vol. 23 (1) , 49-58
Diagnostic Performance of Transrectal, Transvaginal, and Transabdominal Ultrasonography in Pregnancy Diagnosis in Ewes
The aim of this study was to evaluate and compare the diagnostic efficiency of transvaginal (tvUSG) and transabdominal (taUSG) ultrasonography on the 21st, 35th, and 50th days of pregnancy in ewes, using transrectal ultrasonography (trUSG) as the reference method. A total of 100 Awassi ewes in anoestrus were used in the study. Ewes were mated after estrus synchronisation. Pregnancy diagnosis was performed using only tvUSG and trUSG on Day 21 post-mating, whereas on Days 35 and 50, taUSG was additionally applied, allowing the use of all three imaging modalities. In tvUSG, the sensitivity on Days 21, 35, and 50 was 85.71%, 95.34%, and 87.80%, respectively, while specificity remained 100.0% at all time points. The positive predictive value was 100.0%, and the negative predictive value was 87.93%, 96.61%, and 91.18%, respectively. Overall accuracy was calculated as 93.00%, 98.00%, and 95.00% on Days 21, 35, and 50 (Kappa=0.860; 0.959; 0.895, P<0.001). Conversely, taUSG demonstrated a sensitivity of 88.37% on Day 35 and 95.12% on Day 50, with accuracy values of 95.00% and 98.00%, respectively (Kappa 0.897; 0958, P<0.001). When the mean examination times were evaluated, tvUSG had the shortest diagnostic time with 110.03±3.09 seconds and 57.06±1.19 seconds on days 21 and 35, respectively, while taUSG was by far the fastest method with 50.12±1.40 seconds on day 50 (P<0.001). In conclusion, tvUSG emerges as an alternative to trUSG for early pregnancy diagnosis, whereas taUSG is clinically more practical in later stages of gestation due to its ease of application and shorter examination time.
- Open Access
- 12 March 2026
- Published by Springer Nature in Veterinary Research Communications
- Vol. 50 (3)
First clinical use of the kisspeptin analog TAK-683 in the treatment of a follicular cyst in a goat: case report
This case report presents the therapeutic response to TAK‑683, a long-acting kisspeptin analog, in the treatment of a follicular cyst that developed following a conventional estrus synchronization protocol in a goat during the non-breeding season. A two-year-old lactating Aleppo goat showing persistent nymphomaniac behaviour after estrus synchronization was diagnosed with an ovarian follicular cyst by transrectal ultrasonography. The left ovary contained a 17.7 mm thin-walled anechoic cyst, while serum estradiol (14.5 pg/mL) was elevated and progesterone (1.6 ng/mL) was low. The goat was treated with a single subcutaneous dose of the kisspeptin analog TAK-683 (5 µg, Day 0). Therapeutic efficacy was assessed by monitoring ovarian ultrasonography and serum hormones on Days 3, 10, 13, and 17. Following treatment, the cyst underwent luteinization accompanied by a rise in progesterone (peak 6.4 ng/mL) and a decline in estradiol to basal levels, alongside normalization of behaviour. Color Doppler assessment confirmed progressive luteal development and vascularization, followed by natural luteolysis on Day 17 and resumption of follicular activity. In conclusion, this is the first clinical report demonstrating the successful use of TAK‑683 in resolving a follicular cyst in goats. These findings suggest that TAK‑683, beyond its ovulation-inducing role, may offer a promising therapeutic alternative to GnRH agonists for managing reproductive pathologies in veterinary gynaecology.
- 12 March 2026
- Published by Springer Nature in Veterinary Research Communications
- Vol. 50 (3)
Open AccessFirst clinical use of the kisspeptin analog TAK-683 in the treatment of a follicular cyst in a goat: case report
This case report presents the therapeutic response to TAK‑683, a long-acting kisspeptin analog, in the treatment of a follicular cyst that developed following a conventional estrus synchronization protocol in a goat during the non-breeding season. A two-year-old lactating Aleppo goat showing persistent nymphomaniac behaviour after estrus synchronization was diagnosed with an ovarian follicular cyst by transrectal ultrasonography. The left ovary contained a 17.7 mm thin-walled anechoic cyst, while serum estradiol (14.5 pg/mL) was elevated and progesterone (1.6 ng/mL) was low. The goat was treated with a single subcutaneous dose of the kisspeptin analog TAK-683 (5 µg, Day 0). Therapeutic efficacy was assessed by monitoring ovarian ultrasonography and serum hormones on Days 3, 10, 13, and 17. Following treatment, the cyst underwent luteinization accompanied by a rise in progesterone (peak 6.4 ng/mL) and a decline in estradiol to basal levels, alongside normalization of behaviour. Color Doppler assessment confirmed progressive luteal development and vascularization, followed by natural luteolysis on Day 17 and resumption of follicular activity. In conclusion, this is the first clinical report demonstrating the successful use of TAK‑683 in resolving a follicular cyst in goats. These findings suggest that TAK‑683, beyond its ovulation-inducing role, may offer a promising therapeutic alternative to GnRH agonists for managing reproductive pathologies in veterinary gynaecology.
- 17 September 2024
- Published by Wiley in Journal of Veterinary Pharmacology and Therapeutics
- Vol. 48 (1) , 15-21
Effect of Age on the Pharmacokinetics of Marbofloxacin Following Intravenous Administration in Calves
The aim of this study was to compare the pharmacokinetics of marbofloxacin after intravenous (IV) administration of a single dose of 10 mg/kg to calves of different ages. The study was carried on 1‐ (n = 6), 2‐ (n = 6), and 4‐month‐old (n = 6) Montofon calves. Plasma concentrations of marbofloxacin were measured using HPLC, and pharmacokinetic data were calculated by non‐compartmental analysis. The elimination half‐life (t 1/2ʎz ), volume of distribution at steady state (V dss), total clearance (ClT), and area under the concentration‐versus time curve (AUC0–∞) values of marbofloxacin in 1‐month‐old calves were 10.62 h, 1.03 L/kg, 0.08 L/h/kg, and 127.90 h*μg/mL, respectively. While the t 1/2ʎz (from 10.62 to 3.36 h) and AUC0–∞ (from 127.90 to 47.35 h*μg/mL) decreased in parallel with the age of the calves, ClT (from 0.08 to 0.21 L/h/kg) increased. The V dss of marbofloxacin was higher in 1‐ and 2‐month‐old calves compared to 4‐month‐old calves. After IV administration of marbofloxacin at a dose of 10 mg/kg, an ƒAUC0–24/MIC90 ratio of ≥ 125 was obtained for bacteria with MIC90 values of ≤ 0.60, ≤ 0.39 and ≤ 0.27 μg/mL in 1‐, 2‐, and 4‐month‐old calves, respectively. These results show that the antibacterial effect of marbofloxacin, which has concentration‐dependent activity, decreases due to age‐related pharmacokinetic changes and that the 10 mg/kg dose should be reviewed according to the MIC90 value of the bacteria.
- 17 September 2024
- Published by Wiley in Journal of Veterinary Pharmacology and Therapeutics
- Vol. 48 (1) , 15-21
Effect of Age on the Pharmacokinetics of Marbofloxacin Following Intravenous Administration in Calves
The aim of this study was to compare the pharmacokinetics of marbofloxacin after intravenous (IV) administration of a single dose of 10 mg/kg to calves of different ages. The study was carried on 1‐ (n = 6), 2‐ (n = 6), and 4‐month‐old (n = 6) Montofon calves. Plasma concentrations of marbofloxacin were measured using HPLC, and pharmacokinetic data were calculated by non‐compartmental analysis. The elimination half‐life (t 1/2ʎz ), volume of distribution at steady state (V dss), total clearance (ClT), and area under the concentration‐versus time curve (AUC0–∞) values of marbofloxacin in 1‐month‐old calves were 10.62 h, 1.03 L/kg, 0.08 L/h/kg, and 127.90 h*μg/mL, respectively. While the t 1/2ʎz (from 10.62 to 3.36 h) and AUC0–∞ (from 127.90 to 47.35 h*μg/mL) decreased in parallel with the age of the calves, ClT (from 0.08 to 0.21 L/h/kg) increased. The V dss of marbofloxacin was higher in 1‐ and 2‐month‐old calves compared to 4‐month‐old calves. After IV administration of marbofloxacin at a dose of 10 mg/kg, an ƒAUC0–24/MIC90 ratio of ≥ 125 was obtained for bacteria with MIC90 values of ≤ 0.60, ≤ 0.39 and ≤ 0.27 μg/mL in 1‐, 2‐, and 4‐month‐old calves, respectively. These results show that the antibacterial effect of marbofloxacin, which has concentration‐dependent activity, decreases due to age‐related pharmacokinetic changes and that the 10 mg/kg dose should be reviewed according to the MIC90 value of the bacteria.
- 15 November 2023
- Published by Springer Nature in Revista Brasileira de Farmacognosia
- Vol. 34 (2) , 301-312
Safranal's therapeutic effects in rat models of polycystic ovary syndrome
- 15 November 2023
- Published by Springer Nature in Revista Brasileira de Farmacognosia
- Vol. 34 (2) , 301-312
Safranal's therapeutic effects in rat models of polycystic ovary syndrome